rs9263726 is a specific genetic marker for allopurinol-induced severe cutaneous adverse reactions in Chinese patients

Papers of special note have been highlighted as: •• of considerable interest

References

• 1 Gibson T. Hyperuricemia, gout and the kidney. Curr. Opin. Rheumatol. 24(2), 127–131 (2012).
  MedlineGoogle Scholar
• 2 Wortmann RL. Gout and hyperuricemia. Curr. Opin. Rheumatol. 14(3), 281–286 (2002).
  MedlineGoogle Scholar
• 3 Hershfield MS, Callaghan JT, Tassaneeyakul W et al. Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93(2), 153–158 (2013).
  Medline CASGoogle Scholar
• 4 Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129(1), 92–96 (1993).
  Medline CASGoogle Scholar
• 5 French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome: our current understanding. Allergol. Int. 55(1), 9–16 (2006).
  MedlineGoogle Scholar
• 6 Aihara M. Pharmacogenetics of cutaneous adverse drug reactions. J. Dermatol. 38(3), 246–254 (2011).
  Medline CASGoogle Scholar
• 7 Bisht M, Bist SS. Febuxostat: a novel agent for management of hyperuricemia in gout. Indian J. Pharm. Sci. 73(6), 597–600 (2011).
  Medline CASGoogle Scholar
• 8 Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann. Pharmacother. 40(12), 2187–2194 (2006).
  Medline CASGoogle Scholar
• 9 Horikoshi R, Akimoto T, Inoue M, Morishita Y, Kusano E. Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment. Clin. Exp. Nephrol. 17(1), 149–150 (2013).
  MedlineGoogle Scholar
• 10 Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134–4139 (2005).•• The first report that HLA-B*5801 allele strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs) in Han Chinese patients in Taiwan.
  Medline CASGoogle Scholar
• 11 Cheng L, Xiong Y, Qin CZ et al. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study. Br. J. Dermatol. 173(2), 555–558 (2015).
  Medline CASGoogle Scholar
• 12 Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19(9), 704–709 (2009).
  Medline CASGoogle Scholar
• 13 Kang HR, Jee YK, Kim YS et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet. Genomics 21(5), 303–307 (2011).
  Medline CASGoogle Scholar
• 14 Tohkin M, Kaniwa N, Saito Y et al. A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 13(1), 60–69 (2013).•• The first report that several SNPs (rs9263726 among others) around the HLA region on chromosome 6 were strongly linked with HLA-B*5801 allele in Japanese patients.
  Medline CASGoogle Scholar
• 15 Niihara H, Kaneko S, Ito T et al. HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. J. Dermatol. Sci. 71(2), 150–152 (2013).
  Medline CASGoogle Scholar
• 16 Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18(2), 99–107 (2008).
  Medline CASGoogle Scholar
• 17 Saito Y, Stamp LK, Caudle KE et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin. Pharmacol. Ther. doi:10.1002/cpt.161 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 18 Chiu ML, Hu M, Ng MH et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br. J. Dermatol. 167(1), 44–49 (2012).
  Medline CASGoogle Scholar
• 19 Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 43(Database issue), D423–D431 (2015).
  Medline CASGoogle Scholar
• 20 IPD-IMGT/HLA. Statistics. www.ebi.ac.uk/imgt/hla/stats.html.
  Google Scholar
• 21 Maekawa K, Nishikawa J, Kaniwa N et al. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens–Johnson syndrome/toxic epidermal necrolysis in Japanese. Drug Metab. Pharmacokinet. 27(4), 447–450 (2012).
  Medline CASGoogle Scholar
• 22 Yeo SI. HLA-B*5801: utility and cost–effectiveness in the Asia-Pacific region. Int. J. Rheum. Dis. 16(3), 254–257 (2013).
  MedlineGoogle Scholar
• 23 Roujeau JC. The spectrum of Stevens–Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J. Invest. Dermatol. 102(6), 28S–30S (1994).
  Medline CASGoogle Scholar
• 24 Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J. Dtsch. Dermatol. Ges. 7(2), 142–160 (2009).
  MedlineGoogle Scholar
• 25 Palmer D, El Miedany Y. From guidelines to clinical practice: cardiovascular risk management in inflammatory arthritis patients. Br. J. Community Nurs. 18(9), 424–428 (2013).
  MedlineGoogle Scholar
• 26 Liu B, Donovan B, Hocking JS, Knox J, Silver B, Guy R. Improving adherence to guidelines for the diagnosis and management of pelvic inflammatory disease: a systematic review. Infect Dis. Obstet. Gynecol. 2012, 325108 (2012).
  MedlineGoogle Scholar
• 27 Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm. Bowel Dis. 17(10), 2122–2129 (2011).
  MedlineGoogle Scholar
• 28 Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 60(5), 571–607 (2011).
  MedlineGoogle Scholar